RNAM vs. BRK-B

Last updated Jun 4, 2026

RNAM (Avidity Biosciences, Inc.) and BRK-B (Berkshire Hathaway Inc.) are both stocks. RNAM operates in Biotechnology (Healthcare), while BRK-B operates in Insurance - Diversified (Financial Services).

Performance

RNAM vs. BRK-B - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Avidity Biosciences, Inc. (RNAM) and Berkshire Hathaway Inc. (BRK-B). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

RNAM

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

BRK-B

• 1D: 0.82%
• 1M: 1.46%
• YTD: -5.43%
• 6M: -5.61%
• 1Y: -4.51%
• 3Y*: 13.00%
• 5Y*: 10.20%
• 10Y*: 12.91%

*Multi-year figures are annualized to reflect compound growth (CAGR)

RNAM vs. BRK-B - Yearly Performance Comparison

	2026 (YTD)
RNAM Avidity Biosciences, Inc.	0.00%
BRK-B Berkshire Hathaway Inc.	-5.43%

Fundamentals

Market Cap RNAM : $10.87B BRK-B : $1.03T
EPS RNAM : -$4.93 BRK-B : $33.62
PS Ratio RNAM : 539.42 BRK-B : 2.73
PB Ratio RNAM : 6.44 BRK-B : 1.41
Total Revenue (TTM) RNAM : $18.76M BRK-B : $375.39B
Gross Profit (TTM) RNAM : $14.60M BRK-B : $94.36B
EBITDA (TTM) RNAM : -$741.79M BRK-B : $71.92B

Return for Risk

RNAM vs. BRK-B — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BRK-B

BRK-B Risk / Return Rank: 23
BRK-B Sharpe Ratio Rank: 27
BRK-B Sortino Ratio Rank: 22
BRK-B Omega Ratio Rank: 23
BRK-B Calmar Ratio Rank: 24
BRK-B Martin Ratio Rank: 20

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RNAM vs. BRK-B - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Avidity Biosciences, Inc. (RNAM) and Berkshire Hathaway Inc. (BRK-B). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	RNAM	BRK-B	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	-0.32	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.60	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.67	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.48	—

Drawdowns

Drawdown Indicators

	RNAM	BRK-B	Difference
Max Drawdown Largest peak-to-trough decline	—	-53.86%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-9.42%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-14.95%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-26.58%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-29.57%	—
Current Drawdown Current decline from peak	—	-11.94%	—
Average Drawdown Average peak-to-trough decline	—	-11.07%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	4.57%	—

Volatility

Volatility by Period

	RNAM	BRK-B	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	3.75%	—
Volatility (6M) Calculated over the trailing 6-month period	—	10.68%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	14.33%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	17.11%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	19.43%	—

Dividends

RNAM vs. BRK-B - Dividend Comparison

Neither RNAM nor BRK-B has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials